Search Filters

Search Results

Found 1 results

510(k) Data Aggregation

    K Number
    K242919
    Device Name
    V5med Lung AI
    Manufacturer
    Date Cleared
    2025-03-27

    (184 days)

    Product Code
    Regulation Number
    892.2050
    Reference & Predicate Devices
    Why did this record match?
    Device Name :

    V5med Lung AI

    AI/MLSaMDIVD (In Vitro Diagnostic)TherapeuticDiagnosticis PCCP AuthorizedThirdpartyExpeditedreview
    Intended Use

    V5med Lung AI is a Computer-Aided Detection (CAD) software designed to assist radiologists in detecting pulmonary nodules (with diameter of 4-30 mm) during CT examinations of the chest for asymptomatic populations. This software provides adjunctive information to alert radiologists to regions of interest with suspected lung nodules that may otherwise be overlooked. It can be used in a concurrent read mode, where the AI analysis results are displayed alongside the original CT images during either the initial review or any subsequent reviews by the radiologist. V5med Lung AI does not replace the radiologist's critical judgment or diagnostic processes and should not be used in isolation from the original CT series.

    Device Description

    The V5med Lung AI is a software product designed to detect nodules in the lungs. The detection model is trained using a Deep Convolutional Neural Network (CNN) based algorithm, enabling automatic detection of lung nodules ranging from 4 to 30 mm in chest CT images.

    The system integrates algorithm logic and database on the same server, ensuring simplicity and ease of maintenance. It accepts chest CT images from a PACS system, Radiological Information System (RIS), or directly from a CT scanner, analyzes the images, and provides output annotations regarding lung nodules.

    AI/ML Overview

    This document describes the regulatory acceptance criteria met by the V5med Lung AI device and the study conducted to prove its performance.

    1. Table of Acceptance Criteria and Reported Device Performance

    The acceptance criteria for the V5med Lung AI device are implicitly set by the endpoints measured in the clinical performance evaluation, which aimed to demonstrate improved radiologist performance with the AI tool compared to unaided reads. The reported device performance directly addresses these implicit criteria.

    MetricAcceptance Criteria (Implicit)Reported Device Performance (Aided vs Un-aided)Difference (95% CI)Result
    AUC (Localization-Specific ROC)Significant increase in AUC with aid.Unaided: 0.734, Aided: 0.8300.0959 (0.0586, 0.1332)Met (Significant increase, CI entirely above 0)
    Reading Times (seconds)Significant decrease in reading time with aid.Unaided: 133.0, Aided: 115.9-17.1 (-26.7, -9.0)Met (Significant decrease, CI entirely below 0)

    2. Sample Size Used for the Test Set and Data Provenance

    • Test Set Sample Size: 340 chest CT scans.
    • Data Provenance:
      • Country of Origin: Not explicitly stated, but all screening cases were acquired from the NLST (National Lung Screening Trial) CT arm, implying a US-based origin.
      • Retrospective or Prospective: Retrospective. The study was a "retrospective, fully crossed, multi-reader multi-case (MRMC) study."

    3. Number of Experts Used to Establish Ground Truth for the Test Set and Qualifications

    The document does not explicitly state the number of experts used to establish the ground truth for the test set. It mentions sixteen board-certified radiologists participated in the reader study. These radiologists were involved in reading the cases with and without the AI aid, and their performance served as the basis for evaluating the AI's effectiveness.

    4. Adjudication Method for the Test Set

    The document does not explicitly describe an adjudication method for establishing the ground truth for the test set. It mentions a "fully crossed, multi-reader multi-case (MRMC) study" design, where sixteen radiologists read the cases. This implies that the performance metrics (AUC, reading times) were derived from their individual interpretations, likely compared against a pre-established consensus ground truth, though the method for that consensus is not detailed.

    5. If a Multi-Reader Multi-Case (MRMC) Comparative Effectiveness Study Was Done, and Effect Size

    • Yes, a multi-reader multi-case (MRMC) comparative effectiveness study was done.
    • Effect Size of Human Readers Improvement with AI vs. Without AI Assistance:
      • AUC: Radiologists using V5med Lung AI showed a 0.0959 increase in AUC (from 0.734 unaided to 0.830 aided). The 95% confidence interval for this difference was (0.0586, 0.1332), indicating a statistically significant improvement.
      • Reading Times: Radiologists using V5med Lung AI showed a 17.1-second decrease in reading time (from 133.0 seconds unaided to 115.9 seconds aided). The 95% confidence interval for this difference was (-26.7, -9.0), indicating a statistically significant reduction. This translates to approximately a 13% improvement in reading time.

    6. If a Standalone (Algorithm Only Without Human-in-the-Loop Performance) Was Done

    • Yes, standalone performance testing was conducted.
      • The document states: "Standalone performance testing, which included chest CT scans from lung cancer screening population and non-screening population, was conducted to validate detection accuracy of V5med Lung AI."
      • It further notes: "Results showed that V5med Lung AI had similar nodule detection sensitivity compared to those of the predicate device."

    7. The Type of Ground Truth Used

    The document does not explicitly define the type of ground truth used for the standalone performance testing or the MRMC study's assessment of radiologist performance. However, given the context of lung nodule detection in oncology, common ground truth methods include:

    • Expert Consensus: Multiple expert radiologists review cases and reach a consensus on the presence and characteristics of nodules. This is a very common method for CAD device validation. The prompt indicates "consensus" as a possibility.
    • Pathology: Biopsy results confirming the nature of lesions, though this is often not feasible for all identified nodules, especially in large screening datasets.
    • Outcomes Data: Longitudinal follow-up of patients to see if nodules grow or are confirmed to be malignant over time.

    Given the NLST data source, it is highly probable that the ground truth was established through a rigorous process, likely involving expert consensus and potentially correlation with long-term follow-up from the trial, but the specific details are not provided in this excerpt.

    8. The Sample Size for the Training Set

    The document does not provide the sample size for the training set. It only states that the detection model was "trained using a Deep Convolutional Neural Network (CNN) based algorithm."

    9. How the Ground Truth for the Training Set Was Established

    The document does not describe how the ground truth for the training set was established. It only mentions the use of a Deep Convolutional Neural Network (CNN) based algorithm for training the detection model.

    Ask a Question

    Ask a specific question about this device

    Page 1 of 1